Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

HSP27 : une nouvelle cible pour traiter la fibrose pulmonaire idiopathique ?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      CCSD, Accord Elsevier; Lipides - Nutrition - Cancer [Dijon - U1231] (LNC); Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement; Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) (CRMR des maladies pulmonaires rares de l’adulte); Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon]
    • بيانات النشر:
      Elsevier BV, 2020.
    • الموضوع:
      2020
    • نبذة مختصرة :
      Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease without therapeutic options. The development of new therapeutic strategies for the disease is needed. IPF is characterized by myofibroblast accumulation and collagen overproduction. Transforming growth factor-β1 (TGF-β1) is a key cytokine activating these pathological processes. Heat shock proteins (HSPs) are crucial regulators and promote TGF-β1 activity. Among them, HSP27 is overexpressed in animal models and in the lung of patients with IPF. HSP27 activates pro-fibrotic mechanisms and therefore may represents a potential target. Strategies aiming to inhibit HSP27 might pave the way towards new treatment options for patients with IPF.
    • File Description:
      application/pdf
    • ISSN:
      0761-8425
    • الرقم المعرف:
      10.1016/j.rmr.2020.02.007
    • Rights:
      Elsevier TDM
      CC BY NC
    • الرقم المعرف:
      edsair.doi.dedup.....eb6615012478048de8f4f4a3f052e3a9